Trifarotene: First Approval
| Autor: | Lesley J. Scott |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Receptors Retinoic Acid medicine.drug_class Administration Topical Trifarotene Topical treatment Retinoids 03 medical and health sciences 0302 clinical medicine Acne Vulgaris medicine Drug approval Humans Pharmacology (medical) In patient Retinoid Drug Approval Acne Retinoic acid metabolism Molecular Structure business.industry medicine.disease Dermatology Retinoic acid receptor 030220 oncology & carcinogenesis Dermatologic Agents business 030217 neurology & neurosurgery |
| Zdroj: | Drugs. 79:1905-1909 |
| ISSN: | 1179-1950 0012-6667 |
| DOI: | 10.1007/s40265-019-01218-6 |
| Popis: | Topical trifarotene (Aklief®) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink